يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"J. Vermorken"', وقت الاستعلام: 1.04s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.

    المؤلفون: Canon JL; Oncology-Hematology Department, Grand Hopital de Charleroi, 3 Grand Rue, 6000 Charleroi, Belgium. Canon.JL@ghdc.be, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K

    المصدر: Medical oncology (Northwood, London, England) [Med Oncol] 2012 Sep; Vol. 29 (3), pp. 2291-9. Date of Electronic Publication: 2011 Nov 13.

    نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

    بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE

    مواضيع طبية MeSH: Blood Transfusion*, Anemia/*drug therapy , Erythropoietin/*analogs & derivatives , Hematinics/*adverse effects , Hemoglobins/*analysis, Adult ; Aged ; Aged, 80 and over ; Anemia/chemically induced ; Antineoplastic Agents/adverse effects ; Darbepoetin alfa ; Double-Blind Method ; Erythropoietin/administration & dosage ; Erythropoietin/adverse effects ; Female ; Hematinics/administration & dosage ; Humans ; Male ; Middle Aged ; Neoplasms/drug therapy ; Risk ; Young Adult

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.

    المؤلفون: Vansteenkiste J; Respiratory Oncology Unit (Pulmonology), University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. johan.vansteenkiste@uzleuven.be, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B

    المصدر: BMC cancer [BMC Cancer] 2009 Sep 03; Vol. 9, pp. 311. Date of Electronic Publication: 2009 Sep 03.

    نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

    بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

    مواضيع طبية MeSH: Drug-Related Side Effects and Adverse Reactions*, Anemia/*drug therapy , Erythropoietin/*analogs & derivatives , Hematinics/*therapeutic use , Hemoglobins/*metabolism, Adult ; Aged ; Aged, 80 and over ; Anemia/chemically induced ; Anemia/metabolism ; Clinical Trials, Phase III as Topic ; Darbepoetin alfa ; Double-Blind Method ; Erythropoietin/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Retrospective Studies ; Treatment Outcome ; Young Adult

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء